Curatis Holding (26U) Stock Overview
Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 26U from our risk checks.
26U Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Curatis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 20.20 |
| 52 Week High | CHF 28.60 |
| 52 Week Low | CHF 11.20 |
| Beta | -0.81 |
| 1 Month Change | 3.06% |
| 3 Month Change | -21.71% |
| 1 Year Change | 80.36% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 94.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 26U | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.9% | -2.0% | -1.5% |
| 1Y | 80.4% | 40.8% | 4.0% |
Return vs Industry: 26U exceeded the German Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: 26U exceeded the German Market which returned 4.2% over the past year.
Price Volatility
| 26U volatility | |
|---|---|
| 26U Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 26U has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 26U's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 9 | Roland Rutschmann | curatis.com |
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington’s disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and C-FI-01 that is in phase I clinical trial for the treatment of fibrotic or inflammatory orphan or ultra-orphan diseases.
Curatis Holding AG Fundamentals Summary
| 26U fundamental statistics | |
|---|---|
| Market cap | €109.14m |
| Earnings (TTM) | -€1.50m |
| Revenue (TTM) | €11.41m |
Is 26U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 26U income statement (TTM) | |
|---|---|
| Revenue | CHF 10.80m |
| Cost of Revenue | CHF 7.96m |
| Gross Profit | CHF 2.84m |
| Other Expenses | CHF 4.26m |
| Earnings | -CHF 1.42m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 21, 2026
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 26.31% |
| Net Profit Margin | -13.11% |
| Debt/Equity Ratio | 0% |
How did 26U perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 18:24 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Curatis Holding AG is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bob Pooler | ValuationLAB AG |